Title: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Principal Investigators: Ariela Noy, MD, Memorial Sloan Kettering Cancer Center; Lia Palomba, MD, Memorial Sloan Kettering Cancer Center
Description: Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled, phase 3 study to determine if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma (MZL) who have not received previous treatment.
Continue Reading
Researchers will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better. The primary outcome measure of the trial is complete response.
To be eligible for this study, patients must have histologically documented MZL, including splenic, nodal, and extranodal subtypes, and have received no prior systemic therapy for MZL. For a complete list of eligibility criteria, please refer to the reference.
Status: Recruiting
This study is sponsored by Memorial Sloan Kettering Cancer Center in collaboration with Pharmacyclics LLC.
Reference
Clinicaltrials.gov. A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma. NCT04212013. Accessed August 18, 2021.
